A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00401843 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

307

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Siltuximab
DRUG: Bortezomib
DRUG: Placebo
DRUG: Dexamethasone

Sponsor

Janssen Research & Development, LLC